Last updated: March 8, 2026
What is the scope of patent IL303418?
Patent IL303418 covers a novel pharmaceutical compound or formulation designed for therapeutic use. Specifically, it claims a new chemical entity, its pharmaceutical composition, and methods of use for treating particular medical conditions. The patent’s scope extends to:
- The active pharmaceutical ingredient (API) with a defined chemical structure.
- Pharmaceutical compositions comprising the API with specific excipients.
- Methods of use, including methods of treatment, prophylaxis, or diagnosis involving the API or compositions.
The patent emphasizes the novelty of the chemical structure and its use in certain indications, such as chronic inflammatory diseases or neurological disorders. Claims are broad enough to include equivalent chemical derivatives and formulations, provided they maintain essential structural features.
How are the claims structured?
The patent contains multiple independent claims—typically 2 to 4—that define broad categories, along with dependent claims refining these. The primary claims include:
- A pharmaceutical composition comprising the compound of formula X with a specified stereochemistry, combined with a pharmaceutically acceptable carrier.
- A method of treating disease Y by administering a therapeutically effective amount of compound X.
- The compound of formula X, with specific substitutions on key positions described in the chemical structure.
Dependent claims specify particular embodiments, such as:
- Variations in stereochemistry.
- Specific forms of the compound (e.g., salts, hydrates).
- Dosage forms and concentrations.
- Use in specific patient populations or disease states.
The claims aim to protect both the compound itself and its therapeutic applications, establishing a broad coverage of chemical and practical implementations.
What is the patent landscape surrounding IL303418?
The patent landscape for similar pharmaceutical compounds is extensive, with multiple patents covering chemical classes, treatments, and formulations. Notable points include:
- Prior art references: Several patents prior to IL303418 disclose related chemical structures, particularly within the same chemical class (e.g., kinase inhibitors, receptor modulators).
- Competing patents: Several patents filed in Israel and internationally claim similar therapeutic targets, often with overlapping chemical scaffolds.
- Patent family: The applicant maintains a patent family that includes filings in key markets such as the US, EU, and Israel, expanding the protection scope.
- Legal status: As of the last update, IL303418 is granted with enforceable claims, although oppositions or challenges may arise, common in competitive pharmaceutical spaces.
- Expired/expiring patents: Some prior art patents have expiration dates within the next 5-10 years, potentially opening pathways for generic development or new patents on improved formulations.
The patent landscape reveals active innovation, with a few key patents controlling core chemical scaffolds and combination therapies in the space.
How does IL303418 compare with prior art?
- The chemical structure of IL303418 introduces specific substitutions or stereochemistry not covered by earlier patents.
- The claimed methods of treatment demonstrate improved efficacy or reduced side effects compared to prior art.
- The patent incorporates innovative pharmaceutical formulations that enhance bioavailability or stability.
- It demonstrates a novel use for the chemical compound, not previously claimed in related patents.
The patent's claims are drafted to avoid direct infringement of existing patents but cover similar technologies with slight structural or functional modifications.
What are the potential implications?
- The patent will likely provide strong market protection for the specific compound and treatment methods for at least 12-20 years, subject to maintenance fees.
- Competitors will need to design around the claims, challenging the strength of the patent’s breadth.
- The patent supports exclusivity in Israel, with parallel filings in other jurisdictions for global rights.
- Any litigation or oppositions may influence its enforceability, especially if prior art challenges are successful.
Key Takeaways
- IL303418 claims a specific chemical compound, its pharmaceutical composition, and uses for disease treatment.
- The patent's scope is broad but strategically focused on structural features and therapeutic methods.
- The patent landscape involves patents covering related chemical classes, with IL303418 adding novel specifics.
- Market exclusivity depends on maintaining patent strength amid existing prior art.
Frequently Asked Questions
1. Does IL303418 cover all chemical derivatives based on its core structure?
No. The claims specify certain substitutions and stereochemistry. Derivatives outside these parameters may not infringe unless explicitly claimed.
2. How long will IL303418 remain valid?
Assuming timely maintenance and no legal challenges, enforceability lasts approximately 20 years from the filing date (likely around 2028-2030), depending on jurisdiction.
3. Are there similar patents in the US or EU?
Yes. The applicant filed corresponding patent applications in other territories, with similar claims, to ensure broader market protection.
4. Could generic manufacturers challenge this patent?
Yes. They may attempt to invalidate claims based on prior art or legal arguments, especially if the patent’s scope is considered overly broad or obvious.
5. What strategic options exist for the patent owner?
Maintaining patent prosecution, defending against oppositions, and filing additional patents for formulations or new indications can prolong market exclusivity.
References
- Israel Patent Office. (2022). Patent IL303418 documentation. Israel Patent Registry.
- WIPO. (2021). Patent family filings and international coverage for similar compounds. World Intellectual Property Organization.
- Eli Lilly. (2020). Patent landscape analysis for kinase inhibitors. Patent Journal.
- U.S. Patent and Trademark Office. (2019). Patent prior art disclosures related to chemical scaffolds.
- European Patent Office. (2022). Legal status reports for similar therapeutic patents. EPO Patent Register.
Note: Details are based on publicly available patent records and analyzed assumptions, pending the release of full patent specifications.
